Compare Alcon AG (ALC) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs BlackRock TCP Capital Corp — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while BlackRock TCP Capital Corp trades at $3.19 (market cap $268.49M). The key difference: Alcon AG is far larger — about 121.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (26.25%). Which is the better fit depends on your goals.
| ALC | TCPC | |
|---|---|---|
Market Cap | $32.69B | $268.49M |
Sector | Health | Financials |
52-Week High | $92.22 | $7.90 |
52-Week Low | $62.02 | $3.14 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 26.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
TCPC trades at $3.25, down 3.27% on the day, with a bearish technical outlook and negative revenue trends. The stock shows a low price-to-book ratio of 0.48 but faces challenges with negative net income and declining profitability. Recent news highlights a shareholder investigation into fiduciary duties, adding to investor concerns amid mixed analyst sentiment.
The outlook remains cautious due to persistent losses and legal scrutiny. Opportunities exist from the discounted book value and dividend yield, but risks from earnings misses and negative cash flow outweigh near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
